Clinical Oncology Translational Study Phase-1 with Antitumor Phosphorylethanolamine(2-AEH_(2)P)in Dogs with Neoplasms
作者机构:Development and Innovation LaboratoryButantan InstituteAvenue Vital Brasil1500Sao Paulo 05503-900Brazil Faculty of Veterinary Medicine and Animal ScienceSao Paulo UniversitySao Paulo 01246-000Brazil Veretinary Hospital EstimaAvenue Granadeiro GuimaraesTaubaté155Sao PauloBrazil Faculty of Medicine of the University of São PauloSão Paulo 01246-000Brazil
出 版 物:《Journal of Pharmacy and Pharmacology》 (药剂与药理学(英文版))
年 卷 期:2021年第9卷第5期
页 面:179-196页
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:Cancer metabolism phospholipids monophosphoester Fibonacci Model clinical study.
摘 要:The animal has the potential to serve as a clinical model for human disease,due to striking similarities and homologies in *** clinical development of a new drug may influence its final destination,and a careful and thoughtful approach to Phase-1 clinical trials is ***(2-AEH2P)is a new cytostatic phospholipid agent that,unlike most chemotherapeutic drugs used today,does not target DNA or cytoskeleton,but act on the cell *** carried out by our group have shown several effects of 2-AEH2P controlling the progression of the cell cycle,in the alterations of the mitochondrial electrical potential capable of inducing apoptosis and autophagy in several types of human and animal tumor *** aim of this study is to establish the recommended safety dose of a 2-AEH2P monophosphoester,in dogs with tumor following the Phase 1 study model proposed by *** Phase-1 study following the Fibonacci model,2-AEH2P was safe at all staggered doses up to 150 mg/Kg for 8 *** administration in staggered doses according to the Fibonacci model,showed that the drug is safe,no advent of mortality during the study period or acute toxicity were *** is not a drug with hemolytic properties or that induces *** does not lead to changes in liver and renal functions and was able to modulate leukocyte production.2-AEH2P is new compound with antitumor potential,being useful for future veterinary and human tumors,as a combination of chemotherapeutic agents.